Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biocon Chairman Kiran Mazumdar-Shaw On Hopes For An Oral Diabetes Drug, And Risks And Rewards Of Innovation: An Interview with PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Biocon Chairman And Managing Director Kiran Mazumdar-Shaw shares her business development strategy and newest pipeline developments with PharmAsia News in an exclusive interview.

You may also be interested in...

Are Biosimilars The Next Big Opportunity In India?

MUMBAI - The Indian biosimilars market is a multi-billion dollar opportunity for Indian and multinational companies to tap into, albeit via different routes, according to a white paper released this month by global consultancy Frost & Sullivan

India's Biocon Says Primary Endpoints Set For Oral Insulin May Have Been "Harsh"; Reinforces Goal To Develop Drug With Global Partner

MUMBAI - Indian biotechnology firm Biocon has reinforced its ambitions to bring to market an orally delivered insulin and said it stays firmly on track as it found several "unique and positive" takeaways from its recently concluded Phase III clinical trials in India

Biocon's Oral Insulin Fails To Meet Primary Endpoint; Unfazed, Company Says Stage Set For Partnering Talks With Global Pharma

MUMBAI - India's flagship biotechnology company Biocon suffered a significant setback to its most ambitious research project - an orally delivered insulin - that failed to meet its primary end point of lowering HbA1c levels by 0.7 percent in a clinical study concluded recently in India

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts